Incremento de supervivencia en melanoma - page 2

0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 12 24 36 48 60 72 84 96 108 120
Ipilimumab
CENSORED 3-year OS rate, 21% Ipilimumab Pool analysis
Proportion Alive
Months
Melanoma:
Long Term Overall Survival
Schadendorf et al. J Clin Oncol 2015
N=1861